CARMAT
ISIN: FR0010907956 | Ticker: ALCAR | LEI: 969500ARXACM0P0KH333
Country: France
CARMAT is a French MedTech that designs, manufactures and markets the Aeson® artificial heart. The Company’s ambition is to make Aeson® the first alternative to a heart transplant, and thus provide a therapeutic solution to people suffering from end-stage biventricular heart failure, who are facing a well-known shortfall in available human grafts.
The world’s first physiological artificial heart that is highly hemocompatible, pulsatile and self-regulated, Aeson® could save, every year, the lives of thousands of patients waiting for a heart transplant. The device offers patients quality of life and mobility thanks to its ergonomic and portable external power supply system that is continuously connected to the implanted prosthesis. Aeson® is commercially available as a bridge to transplant in the European Union and other countries that recognize CE marking. Aeson® is also currently being assessed within the framework of an Early Feasibility Study (EFS) in the United States.
2008
Served areaWorldwide
HeadquartersImmeuble l'Etendard 36 Avenue de l'Europe, 78141 Vélizy-Villacoublay Cedex – France
| Date | Trading entity / Person | Association | Trade type | Volume |
|---|---|---|---|---|
| 23.10.23 | None | Other | Other | EUR 6,999,991.20 |
| 23.10.23 | None | Other | Other | EUR 3,749,997.60 |
| 23.10.23 | None | Other | Other | EUR 499,996.80 |
| 15.10.23 | None | Other | Other | EUR 3,749,997.60 |
FR0010907956
LEI969500ARXACM0P0KH333
SectorHealth Care Equipment & Services
IndustryHealth Care Equipment & Supplies
Sub-IndustryKeep yourself informed with the most recent updates on FinancialReports, IPOs, product advancements, and other significant news.